Shots: Shionogi to receive $30M upfront ($20M as initial payment & additional $10M in 6mos.) and royalties based on the sales of Symproic. BDSI to get exclusive commercialization rights for […]readmore
Tags : naldemedine
Shots: Sandoz to get commercialization rights for Rizmoic (naldemedine) in Germany, UK and the Netherlands with rights of first refusal for other European markets. Shionogi will be responsible for Rizmoic’s […]readmore